HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The clinical pharmacology of tolmesoxide. A new vasodilator antihypertensive agent.

Abstract
The haemodynamic response and pharmacokinetics of single dose oral tolmesoxide were studied at various dose levels in 4 patients with severe hypertension. There was a reproducible fall in mean arterial pressure from baseline of 24.2% and a rise in heart rate of 37.6% following administration of tolmesoxide. The onset of antihypertensive action occurred within 1 h, with a peak effect at 3 h after dosing. The mean duration of action was up to 12.0 h. Tolmesoxide had a mean half-life of 3.0 h. It was rapidly absorbed with a mean peak plasma level occurring at 1.0 h. Plasma levels correlated well with the doses administered. Side-effects include mild nausea, facial flushing and postural symptoms.
AuthorsC P O'Boyle, M Laher, E T O'Brien, K O'Malley, J G Kelly
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 23 Issue 2 Pg. 93-7 ( 1982) ISSN: 0031-6970 [Print] Germany
PMID6754385 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Sulfoxides
  • tolmesoxide
Topics
  • Aged
  • Antihypertensive Agents (adverse effects, blood, therapeutic use)
  • Blood Pressure (drug effects)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Humans
  • Hypertension (drug therapy)
  • Middle Aged
  • Sulfoxides (adverse effects, blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: